You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 6,936,599

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 6,936,599

Title:	Estriol therapy for multiple sclerosis and other autoimmune diseases
Abstract:	The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, more particularly, Th1-mediated (cell-mediated) autoimmune diseases including: multiple sclerosis (MS), rheumatoid arthritis (RA), autoimmune thyroiditis and uveitis. Most preferably the invention is used to treat a patient with a therapeutically effective amount of estriol of 8 milligrams once daily via oral administration to treat the symptoms or prevent the onset of multiple sclerosis.
Inventor(s):	Voskuhl; Rhonda R. (West Hollywood, CA)
Assignee:	The Regents of the University of California (Oakland, CA)
Application Number:	10/131,834
Patent Claims:	1. A method of treating a patient exhibiting clinical symptoms of multiple sclerosis comprising administering 8 milligrams of estriol orally each 24 hours to ameliorate the disease. 2. The method of claim 1, further comprising administering at least one secondary agent at a therapeutically effective dosage in an effective dosage form at a selected interval. 3. The method of claim 1 wherein the multiple sclerosis is a relapsing remitting form or secondary progressive form of multiple sclerosis. 4. The method of claim 1 wherein the patient is a male or female. 5. A method of treating a patient exhibiting clinical symptoms of multiple sclerosis to ameliorate the disease comprising administering estriol at a dose of about 4 to about 16 milligrams of estriol each 24 hours; and interferon .beta.-1a at a dose of about 0mg to about 30 mcg each week. 6. A method of treating a patient exhibiting clinical symptoms of multiple sclerosis to ameliorate the disease comprising administering estriol at a dose of about 4 to about 16 milligrams of estriol each 24 hours; and interferon .beta.-1b at a dose of about 0 mg to about 0.25 mg every other day.

Details for Patent 6,936,599

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bayer Healthcare Pharmaceuticals Inc.	BETASERON	interferon beta-1b	For Injection	103471	07/23/1993	⤷ Try a Trial	2021-04-25
Biogen Inc.	AVONEX	interferon beta-1a	For Injection	103628	05/17/1996	⤷ Try a Trial	2021-04-25
Biogen Inc.	AVONEX	interferon beta-1a	Injection	103628	05/28/2003	⤷ Try a Trial	2021-04-25
Biogen Inc.	AVONEX	interferon beta-1a	Injection	103628	02/27/2012	⤷ Try a Trial	2021-04-25
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780	03/07/2002	⤷ Try a Trial	2021-04-25
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780	12/17/2004	⤷ Try a Trial	2021-04-25
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780	12/21/2012	⤷ Try a Trial	2021-04-25
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.